In renal carcinoma, in which PHGDH represents the key regulator of the HIF-2α pathway, targeted inactivation of PHGDH may be promising for treating patients resistant to HIF-2α antagonists [134]. The gene discussed is PHGDH; the disease is renal carcinoma.